Invest in our products
TechnoPhage’s strategy is based on developing new therapeutics in early phases of development, with a view to then enter into collaboration deals for pre-clinical or clinical development (or both).
TechnoPhage presents a strong product pipeline supported by a unique international network with leading academic and industry partners as well as renowned CRO and CMO as third party service providers. Its high-quality in-house research activities are supported by consolidated relationships with its wide international network.
The company’s entire pipeline is proprietary and partner companies have variable rights on the asset under development.
TechnoPhage is now entering a new growth stage in its development and is open to external investment for the development of products through to Phase II of clinical trials.